A study of a GLP-1 and GIP medicine, tirzepatide, in people with partial lipodystrophy.
Recruiting now. Registry record last updated September 9, 2025.
- Who can join
- Adults 18+, have partial lipodystrophy.
- What you take
- Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 4 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Lipodystrophy, Partial.
Full scientific study title: Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024.
Who can join
Adults 18+, have partial lipodystrophy. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Patients (≥18 years old) with a diagnosis of familial partial lipodystrophy (per protocol)
- Hemoglobin A1c ≥ 7.0% at screening and after 12-week run-in period and
- Triglycerides ≥ 200 Milligrams Per Deciliter (mg/dL) at screening and after 12-week run-in period
- Stable body weight during the 3 months prior to screening visit (no gain or loss of \>5% current body weight)
- Diet must have been stable for the prior 3 months (i.e., no major change in macronutrient composition, e.g. starting or stopping diets such as Atkins, paleo, vegetarianism, veganism)
Key exclusion criteria
- Diagnosis of generalized lipodystrophy or acquired lipodystrophy
- Having received treatment with a Glucagon-like peptide (GLP) -1 agonist or Tirzepatide within the past 6 months
- History of previous treatment with metreleptin within the past 3 months
- Pancreatitis within the past 3 months
- Patients with a medical history of bone morrow transplant, use of an immune check-point inhibitor, or central nervous system tumor involving the hypothalamus
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Michigan1 site
- University of MichiganAnn Arbor, Michigan
Timeline
Started enrolling: September 8, 2025. Expected completion: September 2029. Last updated on ClinicalTrials.gov: September 9, 2025.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
